Colorectal Cancer | Access and Reimbursement | Brazil/Mexico | 2016

Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy. In Mexico, coverage varies across the different healthcare programs, and in Brazil, the uniqueness of public funding for oncology drugs limits public coverage of treatments. The future will bring an influx of new drugs and biosimilars, and while both countries are eager to adopt new technologies, they have limited budgets. In this increasingly competitive market, only drugs that meet the clinical and economic expectations of both countries will achieve success.This A&R analysis provides key insights for navigating the CRC therapy market in Brazil and Mexico and adapting a branded therapy’s value message to payers and physician needs and expectations in each country.


Clarivate’s Access and Reimbursement module for colorectal cancer in Brazil and Mexico explores the prescribing patterns for current CRC therapies; the potential impact of the anticipated arrival of novel therapies; and key national, regional, and institutional market access factors that will shape the use of CRC therapies over the next two to three years. This report draws on insights from 104 surveyed physicians and from interviews with 6 payers in Brazil and Mexico, all of whom have influence at the institutional, regional, or national level.

Markets covered: Brazil and Mexico.

Primary research:

  • 104 oncologists/medical oncologists
  • 6 payers:
    • Brazil:
      • Senior Member of the Department of Logistics, Purchasing, and Dispensing of Drugs in a reference institution for cancer treatment.
      • Pharmacology Commission member in national reference institution in São Paulo.
      • Head of medical audit department of a major HMO.
    • Mexico
      • National coordinator of Special Programs at ISSSTE.
      • Head of the Department of Oncology at an IMSS hospital.
      • Head of the Department of Medical Oncology at INCAN.

Questions Answered in This Report:

  • What is the public and private healthcare coverage for premium-priced CRC therapies in Brazil and Mexico? How do payers’ policies and infrastructure influence access to specialized healthcare and treatments?
  • What are the current drivers of and barriers to the prescribing of premium-priced CRC therapies? What are the main cost-related/clinical constraints to uptake?
  • What is surveyed physicians’ and payers’ expected pricing of emerging therapies for CRC?
  • How do payers expect access to premium-priced therapies and biosimilars for CRC to evolve in the next three years, and which emerging therapies do payers expect will be covered?
  • How do physicians expect to prescribe emerging agents and biosimilars for CRC? What are these therapies’ likely impact on current brands over the next three years?
  • What clinical benefits do physicians and payers in Brazil and Mexico seek from emerging CRC therapies? What types of savings on direct and indirect costs are payers looking for?
  • What roles will head-to-head and pharmacoeconomic outcomes play in differentiating the reimbursement of high-priced targeted therapies versus currently available targeted therapies?
Login to access report